16:03 EDT CytomX Therapeutics (CTMX) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Varseta-M’s Differentiated Efficacy in Late-Line Colorectal Cancer Drives Higher Approval Odds and Upside to Target Price
- CytomX Therapeutics price target raised to $17 from $10 at H.C. Wainwright
- Midday Fly By: Meta said to eye job cuts, Dollar Tree up after earnings
- CytomX Therapeutics upgraded to Overweight at JPMorgan after late-line CRC data
- CytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan